SELIGENDA Membrane Technologies S.r.L. – an innovative start-up founded in 2020 – is committed to R&D, production and commercialization of innovative and efficient membrane-based separation technologies for applications in biotechnological, biomedical and pharmaceutical fields.

The mission of SELIGENDA, a joint spin-off company of the University of Calabria and Italian National Research Council (CNR), is to revolutionize the current downstream processing (DSP) of biological therapeutics, by developing next-generation membrane systems for the selective purification of monoclonal antibodies (mAbs) and mAbs-related products, coherently with the paradigm of Continuous Manufacturing.

SELIGENDA also acts as Contract Development and Manufacturing Organization for the creation of new specific DSP solutions for medium sized and large pharmaceutical companies, and provides consulting services for design, prototyping and scale-up of membrane operations for tailored applications.


Efrem Curcio, CEO
Oreste Campilongo